ArticleMolecular therapy. Oncology2026

Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.

Lorenz Hanesch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.